RELAPSING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New MS drug shows promise in chinese trial
Disease control CompletedThis study tested a drug called ofatumumab in 99 Chinese adults with relapsing multiple sclerosis (RMS). The goal was to see if monthly injections could reduce the number of relapses and how safe the treatment is. Participants received the drug for 12 months, and researchers trac…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:38 UTC
-
New hope for MS patients: ofatumumab cuts relapses after switching therapies
Disease control CompletedThis study looked at how well ofatumumab works in 562 people with relapsing multiple sclerosis who switched from other MS drugs (fumarates or fingolimod) because their disease was still active. The main goal was to see how many relapses occurred per year. Researchers also tracked…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:37 UTC
-
MS drug shows promise in long-term safety extension trial
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug SAR442168 in 125 people with relapsing multiple sclerosis who had already completed a previous study. Participants continued taking the drug for up to 240 weeks. The main goal was to track side effects, and t…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated May 17, 2026 11:31 UTC
-
MS patients successfully switch to At-Home injection, study finds
Disease control CompletedThis study looked at whether people with relapsing multiple sclerosis (MS) could safely switch from an IV infusion therapy to a self-injected drug called ofatumumab and still keep their MS under control. Over 100 adults took part, and after 12 months, most had no new or worsening…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New MS drug shows promise in shrinking brain lesions
Disease control CompletedThis study tested a new medication called SAR442168 in 130 adults with relapsing multiple sclerosis. The goal was to find the best dose to reduce new active brain lesions seen on MRI scans. Participants received the drug or a placebo for 12 to 16 weeks, and researchers measured c…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Real-World data reveals how MS patients stick with kesimpta treatment
Knowledge-focused CompletedThis study observed 103 adults with relapsing multiple sclerosis who were taking Kesimpta (ofatumumab). Researchers used data from a patient support app to see how consistently people took their medication and how their symptoms and quality of life changed over time. The goal was…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 17, 2026 11:33 UTC
-
MS Drug's brain impact revealed in small study
Knowledge-focused CompletedThis study looked at how ofatumumab, a multiple sclerosis (MS) drug, affects immune cells in the brain called microglia. Ten adults with relapsing MS had special brain scans and blood tests over 9 months. The goal was to understand how the drug works in the brain, not to test if …
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC